1. 目前位置：

完整後設資料紀錄
DC 欄位值語言
dc.contributor.authorChou, Feng-Paien_US
dc.contributor.authorHsu, Wen-Chenen_US
dc.contributor.authorHuang, Sheng-Cihen_US
dc.contributor.authorChang, Chin-Yuanen_US
dc.contributor.authorChiou, Ya-Shengen_US
dc.contributor.authorTsai, Chia-Tseen_US
dc.contributor.authorLyu, Jason WenJayen_US
dc.contributor.authorChen, Wei-Tingen_US
dc.contributor.authorWu, Tung-Kungen_US
dc.date.accessioned2020-03-02T03:23:27Z-
dc.date.available2020-03-02T03:23:27Z-
dc.date.issued2020-02-07en_US
dc.identifier.issn1359-7345en_US
dc.identifier.urihttp://dx.doi.org/10.1039/c9cc09415fen_US
dc.identifier.urihttp://hdl.handle.net/11536/153728-
dc.description.abstractWe report here that pregnenolonyl-alpha-glucoside (2), a steryl glycoside synthesized directly from pregnenolone and glucose via a consecutive multienzyme-catalyzed process, exhibits marked dose-dependent cytotoxic activity against HT29, AGS, and ES-2 cells with IC50 values of 23.5 to 50.9 mu M. An in vitro CYP17A1 binding pattern assay and protein-ligand docking model support that 2, like abiraterone, binds in the active site heme iron pocket of CYP17A1.en_US
dc.language.isoen_USen_US
dc.titlePregnenolonyl-alpha-glucoside exhibits marked anti-cancer and CYP17A1 enzymatic inhibitory activitiesen_US
dc.typeArticleen_US
dc.identifier.doi10.1039/c9cc09415fen_US
dc.identifier.journalCHEMICAL COMMUNICATIONSen_US
dc.citation.volume56en_US
dc.citation.issue11en_US
dc.citation.spage1733en_US
dc.citation.epage1736en_US
dc.contributor.department交大名義發表zh_TW
dc.contributor.department生物科技學系zh_TW
dc.contributor.departmentNational Chiao Tung Universityen_US
dc.contributor.departmentDepartment of Biological Science and Technologyen_US
dc.identifier.wosnumberWOS:000513177300024en_US
dc.citation.woscount0en_US
顯示於類別：期刊論文


相關內容
Loading...